Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

γ-Carbolines: a novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration.

Cheng YX, Pourashraf M, Luo X, Srivastava S, Walpole C, Salois D, St-Onge S, Payza K, Lessard E, Yu XH, Tomaszewski MJ.

Bioorg Med Chem Lett. 2012 Feb 15;22(4):1619-24. doi: 10.1016/j.bmcl.2011.12.124. Epub 2012 Jan 4.

PMID:
22284817
2.

A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain.

Yu XH, Cao CQ, Martino G, Puma C, Morinville A, St-Onge S, Lessard E, Perkins MN, Laird JM.

Pain. 2010 Nov;151(2):337-44. doi: 10.1016/j.pain.2010.07.019. Epub 2010 Aug 8.

PMID:
20696525
3.

Antihyperalgesic properties of the cannabinoid CT-3 in chronic neuropathic and inflammatory pain states in the rat.

Dyson A, Peacock M, Chen A, Courade JP, Yaqoob M, Groarke A, Brain C, Loong Y, Fox A.

Pain. 2005 Jul;116(1-2):129-37.

PMID:
15936883
4.

Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: a potent, orally bioavailable human CB1/CB2 dual agonist with antihyperalgesic properties and restricted central nervous system penetration.

Dziadulewicz EK, Bevan SJ, Brain CT, Coote PR, Culshaw AJ, Davis AJ, Edwards LJ, Fisher AJ, Fox AJ, Gentry C, Groarke A, Hart TW, Huber W, James IF, Kesingland A, La Vecchia L, Loong Y, Lyothier I, McNair K, O'Farrell C, Peacock M, Portmann R, Schopfer U, Yaqoob M, Zadrobilek J.

J Med Chem. 2007 Aug 9;50(16):3851-6. Epub 2007 Jul 14.

PMID:
17630726
5.

N-Methyl-3-(tetrahydro-2H-pyran-4-yl)-2,3,4,9-tetrahydro-1H-carbazole-6-carboxamides as a novel class of cannabinoid receptors agonists with low CNS penetration.

Wei Z, Yang H, Liu Z, Tremblay M, Johnstone S, Béha S, Yue SY, Srivastava S, Tomaszewski MJ, Brown W, Walpole C, St-Onge S, Lessard E, Archambault AJ, Groblewski T, Pagé D.

Bioorg Med Chem Lett. 2012 Jun 15;22(12):3884-9. doi: 10.1016/j.bmcl.2012.04.128. Epub 2012 May 4.

PMID:
22607668
6.

Decahydroquinoline amides as highly selective CB2 agonists: role of selectivity on in vivo efficacy in a rodent model of analgesia.

Manley PJ, Zartman A, Paone DV, Burgey CS, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT, Trotter BW.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2359-64. doi: 10.1016/j.bmcl.2011.02.078. Epub 2011 Feb 26.

PMID:
21420857
7.

A molecular basis of analgesic tolerance to cannabinoids.

Tappe-Theodor A, Agarwal N, Katona I, Rubino T, Martini L, Swiercz J, Mackie K, Monyer H, Parolaro D, Whistler J, Kuner T, Kuner R.

J Neurosci. 2007 Apr 11;27(15):4165-77.

8.

Imidazopyridine CB2 agonists: optimization of CB2/CB1 selectivity and implications for in vivo analgesic efficacy.

Trotter BW, Nanda KK, Burgey CS, Potteiger CM, Deng JZ, Green AI, Hartnett JC, Kett NR, Wu Z, Henze DA, Della Penna K, Desai R, Leitl MD, Lemaire W, White RB, Yeh S, Urban MO, Kane SA, Hartman GD, Bilodeau MT.

Bioorg Med Chem Lett. 2011 Apr 15;21(8):2354-8. doi: 10.1016/j.bmcl.2011.02.082. Epub 2011 Mar 1.

PMID:
21420860
9.

Discovery and optimization of a novel series of N-arylamide oxadiazoles as potent, highly selective and orally bioavailable cannabinoid receptor 2 (CB2) agonists.

Cheng Y, Albrecht BK, Brown J, Buchanan JL, Buckner WH, DiMauro EF, Emkey R, Fremeau RT Jr, Harmange JC, Hoffman BJ, Huang L, Huang M, Lee JH, Lin FF, Martin MW, Nguyen HQ, Patel VF, Tomlinson SA, White RD, Xia X, Hitchcock SA.

J Med Chem. 2008 Aug 28;51(16):5019-34. doi: 10.1021/jm800463f. Epub 2008 Aug 5.

PMID:
18680277
10.

A survey of recent patents on CB2 agonists in the management of pain.

Murineddu G, Asproni B, Pinna GA.

Recent Pat CNS Drug Discov. 2012 Apr 1;7(1):4-24. Review.

PMID:
22280338
11.

Targeting cannabinoid agonists for inflammatory and neuropathic pain.

Cheng Y, Hitchcock SA.

Expert Opin Investig Drugs. 2007 Jul;16(7):951-65. Review.

PMID:
17594182
12.

Therapeutic potential of cannabinoid receptor agonists as analgesic agents.

Fox A, Bevan S.

Expert Opin Investig Drugs. 2005 Jun;14(6):695-703. Review.

PMID:
16004597
13.

Control of pain initiation by endogenous cannabinoids.

Calignano A, La Rana G, Giuffrida A, Piomelli D.

Nature. 1998 Jul 16;394(6690):277-81.

PMID:
9685157
14.
15.
16.

[The cannabinoid system and pain: towards new drugs?].

Beltramo M.

J Soc Biol. 2009;203(1):99-106. doi: 10.1051/jbio:2009002. Epub 2009 Apr 10. Review. French.

PMID:
19358815
17.

Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors.

Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr.

Anesthesiology. 2003 Oct;99(4):955-60.

PMID:
14508331
18.

Discovery of agonists of cannabinoid receptor 1 with restricted central nervous system penetration aimed for treatment of gastroesophageal reflux disease.

Plowright AT, Nilsson K, Antonsson M, Amin K, Broddefalk J, Jensen J, Lehmann A, Jin S, St-Onge S, Tomaszewski MJ, Tremblay M, Walpole C, Wei Z, Yang H, Ulander J.

J Med Chem. 2013 Jan 10;56(1):220-40. doi: 10.1021/jm301511h. Epub 2012 Dec 24.

PMID:
23227781
19.

Discovery of 1-[4-(3-chlorophenylamino)-1-methyl-1H-pyrrolo[3,2-c]pyridin-7-yl]-1-morpholin-4-ylmethanone (GSK554418A), a brain penetrant 5-azaindole CB2 agonist for the treatment of chronic pain.

Giblin GM, Billinton A, Briggs M, Brown AJ, Chessell IP, Clayton NM, Eatherton AJ, Goldsmith P, Haslam C, Johnson MR, Mitchell WL, Naylor A, Perboni A, Slingsby BP, Wilson AW.

J Med Chem. 2009 Oct 8;52(19):5785-8. doi: 10.1021/jm9009857.

PMID:
19743867
20.

A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.

Whiteside GT, Gottshall SL, Boulet JM, Chaffer SM, Harrison JE, Pearson MS, Turchin PI, Mark L, Garrison AE, Valenzano KJ.

Eur J Pharmacol. 2005 Dec 28;528(1-3):65-72. Epub 2005 Nov 28.

PMID:
16316650
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk